Baseline patient demographics and characteristics
| . | Total . | Imatinib-resistant . | Imatinib-intolerant . |
|---|---|---|---|
| n | 186 | 127 | 59 |
| Median age, y (range) | 59 (24-79) | 59 (24-79) | 59 (24-79) |
| Male sex, % | 46 | 47 | 44 |
| Median duration of CML, mo | 64 | 77 | 26 |
| Imatinib therapy duration, % | |||
| Less than 1 y | 20 | 5 | 54 |
| 1-3 y | 26 | 24 | 31 |
| At least 3 y | 54 | 72 | 15 |
| Highest imatinib dose, % | |||
| 400-600 mg | 48 | 27 | 93 |
| At least 600 mg | 52 | 73 | 7 |
| Prior chemotherapy, % | 42 | 50 | 25 |
| Prior interferon-α, % | 70 | 77 | 54 |
| Prior SCT, % | 9 | 10 | 7 |
| Median WBC count/nL (range) | 9.9 (0.4-196.5) | 11.9 (0.4-196.5) | 7.4 (2.0-182.7) |
| WBC count at least 20×109/L, % | 30 | 38 | 14 |
| Median platelets/nL (range) | 290 (24-1912) | 300 (24-1912) | 254 (61-1165) |
| Median basophils in PB, % (range) | 2 (0-20) | 3 (0-18) | 1 (0-20) |
| . | Total . | Imatinib-resistant . | Imatinib-intolerant . |
|---|---|---|---|
| n | 186 | 127 | 59 |
| Median age, y (range) | 59 (24-79) | 59 (24-79) | 59 (24-79) |
| Male sex, % | 46 | 47 | 44 |
| Median duration of CML, mo | 64 | 77 | 26 |
| Imatinib therapy duration, % | |||
| Less than 1 y | 20 | 5 | 54 |
| 1-3 y | 26 | 24 | 31 |
| At least 3 y | 54 | 72 | 15 |
| Highest imatinib dose, % | |||
| 400-600 mg | 48 | 27 | 93 |
| At least 600 mg | 52 | 73 | 7 |
| Prior chemotherapy, % | 42 | 50 | 25 |
| Prior interferon-α, % | 70 | 77 | 54 |
| Prior SCT, % | 9 | 10 | 7 |
| Median WBC count/nL (range) | 9.9 (0.4-196.5) | 11.9 (0.4-196.5) | 7.4 (2.0-182.7) |
| WBC count at least 20×109/L, % | 30 | 38 | 14 |
| Median platelets/nL (range) | 290 (24-1912) | 300 (24-1912) | 254 (61-1165) |
| Median basophils in PB, % (range) | 2 (0-20) | 3 (0-18) | 1 (0-20) |
CML indicates chronic myeloid leukemia; PB, peripheral blood; SCT, stem-cell transplantation; WBC, white blood cell.